Novo Nordisk A/S Shares Drop on U.S. Scrutiny of Insulin Drug

Published: Oct 29, 2012

Novo Nordisk A/S | Jobs at Novo Nordisk A/S

Shares in Denmark's Novo Nordisk fell as much as 5 percent on Friday, after a U.S. expert panel assessing the group's ultra long-acting insulin degludec said it will study the cardiovascular safety of the drug.

The statement late on Thursday raised a potential obstacle to approval of the drug, which Novo plans to market under the brand name Tresiba, in the world's top market ahead of the panel's meeting on November 8.

Back to news